Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 4 (TRAV4) is a **variable region gene segment** of the alpha chain of the T cell receptor (TCR) complex, predominantly expressed on the surface of T lymphocytes as part of the alpha-beta TCR heterodimer[1][2][3]. The TCR enables T cells to recognize and bind to specific antigen fragments presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, initiating essential signaling cascades for immune activation[1][2]. TRAV4, like other TCR variable segments, contributes to the diversity of antigen recognition via V(D)J recombination, allowing the immune system to respond to a vast array of pathogens[2][3]. Members of the TCR family are central to **adaptive immunity**, are classified as **immunoglobulin superfamily receptors**, and play direct roles in anti-infective and antitumor immune function. Dysfunction or dysregulation of TCRs, including those with TRAV4, can result in immune deficiencies, autoimmune diseases, or aberrant immune activation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 4 (TRAV4).